SHERIDAN, WYOMING - April 9, 2026 - Medtech supply chains across North America depend on the continued operation of the United States-Mexico-Canada Agreement, and a formal renewal keeps tariff predictability intact for the more than 650 medtech and health tech companies that AdvaMed represents - the majority of them small businesses.
Why USMCA matters to the medtech sector
The U.S. medtech industry spans manufacturing, research and development, and global healthcare delivery. Cross-border supply chains between the United States, Mexico, and Canada underpin both domestic production and the export leadership that U.S. medtech companies hold internationally. Without a stable trilateral trade framework, manufacturers face uncertainty in sourcing components, managing regulatory timelines, and forecasting capital investments.
USMCA has been operative for several years, giving companies a planning horizon they could use to allocate production capacity, negotiate supplier contracts, and build workforce pipelines. That continuity, according to AdvaMed President and CEO Scott Whitaker, is the agreement's most operationally significant feature for the industry: companies need predictability and certainty on trade and tariff policy to make the investment decisions necessary to create jobs and maintain their supply chains.
AdvaMed's position on renewal and regulatory convergence
AdvaMed expressed explicit support for USMCA renewal, framing the agreement as a mechanism that reinforces U.S. leadership in medtech innovation and production while sustaining the supply chains required to serve American patients. The association also acknowledged the role of the U.S. Senate Committee on Finance, specifically Chairman Crapo and Ranking Member Wyden, in convening a hearing that examined USMCA's benefits and areas where implementation could be strengthened.
Key improvement areas cited include regulatory convergence across the three partner nations and broader adoption of sound trade practices. Regulatory convergence is particularly consequential for medtech: differing approval pathways, labeling requirements, and post-market surveillance obligations in the U.S., Mexico, and Canada create compliance overhead that raises costs and slows time-to-market for device manufacturers operating across all three jurisdictions.
Mexico and Canada as supply-chain and export partners
Mexico functions as a critical manufacturing and assembly hub for U.S. medtech companies, particularly for single-use devices, diagnostics components, and lower-complexity instruments where labor cost structures favor cross-border production arrangements. Canada serves as both a key export destination and a source of advanced research partnerships, particularly in imaging, diagnostics, and digital health technologies.
USMCA's rules-of-origin provisions directly affect how medtech companies structure their production networks. Tariff-free access depends on meeting content thresholds, which shapes decisions about where components are sourced and where final assembly occurs. A renewed agreement preserves those thresholds and the trade flows built around them, avoiding the disruption that would accompany renegotiation under ambiguous interim conditions.
Business impact
Supply chain officers at medtech manufacturers - particularly those operating facilities or sourcing across Mexico and Canada - can treat USMCA renewal as a green light to extend existing cross-border supplier contracts and defer contingency restructuring costs that would otherwise be triggered by agreement expiration. Companies that had held back on capital commitments tied to North American production expansion now have a clearer basis for proceeding with those investments through 2026 budget cycles.
Regulatory affairs and market access teams face a near-term action item: tracking any new regulatory convergence provisions that emerge from the Senate Finance Committee's review process. If the renewal incorporates updated convergence language, device classification, labeling, and post-market reporting workflows across all three markets may need to be realigned. Procurement leads managing tariff exposure should also monitor any revised rules-of-origin thresholds, which could alter component sourcing decisions and landed cost calculations for products assembled in Mexico or Canada for U.S. distribution.